AzTrials
AzTrials

Colitis, UlcerativePhase 2NCT02601300

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

A Phase 2 study testing GED-0301 in people with Colitis, Ulcerative, run by Celgene at 36 sites in 6 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a phase 2, open-label, multicenter study to explore the efficacy and safety of oral GED- 0301 in subjects with active UC, defined as a modified Mayo score (MMS) ≥ 4 and ≤ 9 and a Mayo endoscopic subscore≥ 2. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Colitis, Ulcerative
What is being tested?
GED-0301
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
41 participants
Where
36 sitesin 6 countries
Study dates
14 Dec 2015to 8 Aug 2017
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subjects must satisfy the following criteria to be enrolled in the study:
  • Subject is ≥ 18 years of age at the time of signing the informed consent form (ICF).
  • Subject is able to understand and voluntarily sign an informed consent form (ICF)prior to conducting any study related assessments/procedures.
  • Subject is willing and able to adhere to the study visit schedule and other protocol requirements.
  • Subject must have diagnosis of Ulcerative Colitis (UC) with a duration of at least 3 months prior to screening.
  • Subject must have moderate to severe Ulcerative Colitis (UC), defined as Modified Mayo score (MMS) ≥ 4 to ≤ 9 with rectal bleeding subscore (RBS) ≥ 1 at screening.
Show all 19Show fewer
  • Subject must have a Mayo endoscopic subscore ≥ 2 at screening.
  • Subject must have failed or experienced intolerance to at least one of the following:
  • aminosalicylates; budesonide; systemic corticosteroids; immunosuppressants (eg,6-mercaptopurine (6-MP), or azathioprine (AZA)) or Tumor necrosis factor (TNF)-α blockers (eg, infliximab, adalimumab, or golimumab)
  • Subject must meet the following laboratory criteria:
  • White blood cell count ≥ 3000/mm3 (≥ 3.0 X 109/L)
  • Platelet count ≥ 100,000/mm3 (≥ 100 X 109/L)
  • Serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L)
  • Aspartate transaminase (AST/serum glutamic oxaloacetic transaminase (SGOT)) and alanine transaminase (ALT/serum pyruvic transaminase (SGPT)2.5 X upper limit of normal (ULN)
  • Total bilirubin ≤ 2 mg/dL (≤ 34 μmol/L) unless there is a confirmed diagnosis of Gilbert's disease
  • Hemoglobin ≥ 9 g/dL (≥ 5.6 mmol/L)
  • Activated partial thromboplastin time (APTT) 1.5 X ULN
  • Females of childbearing potential (FCBP) must have a negative pregnancy test at the Screening and Baseline Visits. While on Investigational Product (IP)and for at least 28 days after taking the last dose of Investigational Product (IP), females of childbearing potential (FCBP) who engage in activity in which conception is possible must use one of the approved contraceptive options described below: Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR Option 2: Male or female condom PLUS 1 additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.
  • Male subjects (including those who have had a vasectomy) when engaging in sexual activity with females who are able to become pregnant must use barrier contraception (male latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]) while on Investigational Product (IP) and for at least 28 days after the last dose.

Who cannot join

  • The presence of any of the following will exclude a subject from enrollment:
  • Subject has a diagnosis of Crohn's Disease (CD), indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis.
  • Subject has ulcerative colitis restricted to distal 15 cm or less (eg, ulcerative proctitis).
  • Subject had surgery as a treatment for ulcerative colitis (UC)or who, in the opinion of the Investigator, is likely to require surgery for ulcerative colitis (UC) during the study.
  • Subject has clinical signs suggestive of fulminant colitis or toxic megacolon.
  • Subject is stool positive for any enteric pathogen or Clostridium difficile (C. difficile) toxin at screening.
Show all 27Show fewer
  • Subject has history of colorectal cancer or colorectal dysplasia.
  • Prior treatment with more than 2 Tumor necrosis factor (TNF)-α blockers (eg, infliximab, adalimumab, or golimumab).
  • Prior treatment with any integrin antagonists (eg, natalizumab or vedolizumab).
  • Use of Tumor necrosis factor (TNF)-α blockers within 8 weeks of the screening.
  • Subject had prior treatment with mycophenolic acid, tacrolimus, sirolimus, cyclosporine, thalidomide or apheresis (eg, Adacolumn®) for the treatment of ulcerative colitis (UC). In addition, prior use of any of these treatment modalities for an indication other than ulcerative colitis (UC) within 8 weeks of screening is also excluded.
  • Subject has received intravenous (IV) corticosteroids within 2 weeks of screening.
  • Subject has received topical treatment with 5 aminosalicylic acid (5-ASA) or corticosteroid enemas or suppositories within 2 weeks of screening.
  • Subject has received total parenteral nutrition (TPN) within 4 weeks of screening.
  • Subject has a history of any clinically significant neurological, renal, hepatic, gastrointestinal, pulmonary, metabolic, cardiovascular, psychiatric, endocrine, hematological disorder or disease, or any other medical condition that, in the investigator's opinion, would prevent the subject from participation in the study.
  • Subject has any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she was to participate in the study or confounds the ability to interpret data from the study.
  • Subject is pregnant or breastfeeding.
  • Subject has a history of any of the following cardiac conditions within 6 months of screening: myocardial infarction, acute coronary syndrome, unstable angina, new onset atrial fibrillation, new onset atrial flutter, second- or third-degree atrioventricular block, ventricular fibrillation, ventricular tachycardia, heart failure, cardiac surgery, interventional cardiac catheterization (with or without a stent placement), interventional electrophysiology procedure, or presence of implanted defibrillator.
  • Subject has a known active current or history of medically important recurrent bacterial, viral, fungal, mycobacterial or other infections (including but not limited to tuberculosis and atypical mycobacterial disease and Herpes zoster), human immunodeficiency virus (HIV), or any major episode of infection requiring hospitalization or treatment with intravenous (IV) or oral antibiotics within 4 weeks of screening.
  • Subject has a history of congenital or acquired immunodeficiency (eg, common variable immunodeficiency disease).
  • Subject has a history of malignancy, except for:
  • Treated (ie, cured) basal cell or squamous cell in situ skin carcinomas
  • Treated (ie, cured) cervical intraepithelial neoplasia or carcinoma in situ of the cervix with no evidence of recurrence within the previous 5 years
  • Subject has received investigational drug or device within 1 month of screening.
  • Subject has a history of alcohol, drug, or chemical abuse within the 6 months prior to screening.
  • Subject has a known hypersensitivity to oligonucleotides or any ingredient in the Investigational Product (IP).
  • Subject has prior treatment with GED-0301 or participated in a clinical study involving GED-0301.

Trial locations and contacts

36 sites in 6 countries.

36 sites in 6 countries

United States20 sites

  • Chevy Chase Clinical Research

    Chevy Chase, Maryland, 20815

  • Case Western Reserve University

    Cleveland, Ohio, 44106

  • Texas Digestive Disease Consultants - Dallas

    Dallas, Texas, 75231

  • Florida Research Network, LLC

    Gainesville, Florida, 32605

  • Gastroenterology Center of The Midsouth PC

    Germantown, Tennessee, 38138

  • Baylor College of Medicine

    Houston, Texas, 77030

  • Dartmouth Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

  • University of Kentucky

    Lexington, Kentucky, 40536

  • Dean Medical Center

    Madison, Wisconsin, 53715

  • University of Miami School of Medicine

    Miami, Florida, 33136

  • Gastroenterology Group of Naples

    Naples, Florida, 34102

  • Nashville Gastrointestinal Specialists

    Nashville, Tennessee, 37211

  • Vanderbilt University

    Nashville, Tennessee, 37212

  • Concorde Medical Group

    New York, New York, 10016

  • Macks Research Group

    Newport Beach, California, 92660

  • McGuire Veterans Affairs Medical Center

    Richmond, Virginia, 23249

  • Rochester General Hospital

    Rochester, New York, 14621

  • Medical Associates Research Associates

    San Diego, California, 92123

  • Texas Digestive Disease Consultants - Southlake

    Southlake, Texas, 76092

  • Shafran Gastroenterology Center

    Winter Park, Florida, 32789

Other trials in United States

Slovakia5 sites

  • Fakultna nemocnica s poliklinikou F. D. Roosevelta

    Banská Bystrica, 975 17

  • Univerzitna nemocnica Bratislava

    Bratislava, 82606

  • IBD Centrum s.r.o.

    Bratislava, 83104

  • KM Management, spol. s r.o.

    Nitra, 949 01

  • GASTRO I., s.r.o.

    Prešov, 080 01

Other trials in Slovakia

Poland4 sites

  • Centrum Medyczne sw. Lukasza

    Częstochowa, 42-200

  • Endoskopia Sp. z o.o.

    Sopot, 81-756

  • Centrum Zdrowia Matki, Dziecka i Mlodziezy

    Warsaw, 00-632

  • LexMedica Osrodek Badan Klinicznych

    Wroclaw, 53-025

Other trials in Poland

Bulgaria3 sites

  • Multiprofile Hospotal for Active Treatment- Sveti Nikolay Chudotvoretz - LOM EOOD

    Lom, 3600

  • Multiprofile Hospital for Active Treatment Doverie AD

    Sofia, 1632

  • Multiprofile Hospital for Active Treatment Sveti Panteleimon - Sofia AD

    Sofia, 1712

Other trials in Bulgaria

Canada3 sites

  • London Health Sciences Centre, University Hospital

    London, Ontario, N6A 5A5

  • GI Research Institute

    Vancouver, British Columbia, V6Z 2K5

  • Toronto Digestive Disease Associates Inc

    Vaughan, Ontario, L4L 4Y7

Other trials in Canada

Hungary1 site

  • Pandy Kalman Megyei Korhaz

    Siófok, 8600

Other trials in Hungary

About this study

Official title: A Phase 2, Open-Label, Multicenter Study to Explore the Efficacy and Safety of MONGERSON (GED-0301) in Subjects With Active Ulcerative Colitis.

This is a phase 2, open-label, multicenter study to explore the efficacy and safety of oral GED- 0301 in subjects with active UC, defined as a modified Mayo score (MMS) ≥ 4 and ≤ 9 and a Mayo endoscopic subscore≥ 2.

Approximately 40 subjects will be enrolled using an Interactive Voice Response System (IVRS) or an Interactive Web Response System (IWRS) to receive open-label, oral GED-0301 160 mg for duration of 52 week treatment. Enrollment of subjects with previous exposure to TNF-α blockers will be limited to approximately 15 subjects. The number of subjects with extensive colitis is targeted to comprise approximately 50% of the entire study population.

Read the detailed description

Eligible subjects will have the Baseline Visit (Week 0/ Visit 2) and receive the following treatments:

  • Induction Phase - GED-0301 160 mg once daily (QD) for 8 weeks;
  • Extension Phase - GED-0301 160 mg on alternating dosing schedule (GED-0301 160 mg QD for 4 weeks, followed by 4 weeks without GED-0301 treatment) for an additional 44 weeks. Subjects who do not achieve at least a 20% decrease in partial mayo score (PMS) from baseline at Week 12 will be discontinued from the study.

Clinical, safety, and pharmacokinetic (PK) data will be evaluated on an ongoing basis, however, if the response to treatment is lower than expected (eg, ≤2 subjects achieving clinical remission based on modified Mayo score (MMS)) when 50% of the subjects complete Week 8, or discontinue before Week 8, the study team will review available data (clinical, safety, and PK) to evaluate if the study conduct should be modified.

This evaluation will be based on clinical judgment and the following guidance

  • Consider starting a new cohort of subjects using a QD dose up to 320 mg if there is endoscopic or histologic evidence of proximal colon benefit but limited or no distal colon drug exposure/efficacy. Also, there is evidence of potential overall efficacy (total Mayo score (TMS), MMS,PMS) outcomes and acceptable safety (adverse events (AEs)/vitals/clinical laboratory test results) and exposure (PK).
  • Consider to terminate the study if there is no evidence of drug exposure/efficacy in the colon observed by endoscopy or biopsy nor evidence of potential overall efficacy (TMS, MMS, PMS) outcomes or unacceptable safety(AEs/labs/vitals) or exposure (PK).
  • Continue the study with the GED-0301 160 mg QD dose. If the GED-0301 160 mg QD dose group is discontinued and a new dose group is added, an additional 40 subjects will be enrolled in the new dose group. Subjects enrolled subsequent to the decision to adjust the dose of GED-0301, will receive the following treatments:
  • Induction Phase - GED-0301, up to 320 mg QD, for 8 weeks;
  • Extension Phase- GED-0301, up to 320 mg on alternating dosing schedule (GED-0301, up to 320 mg QD for 4 weeks, followed by 4 weeks without GED-0301 treatment) for an additional 44 weeks. Subjects who do not achieve at least a 20% decrease in the PMS from baseline at Week 12 will be discontinued from the study. Actively enrolled subjects will not be affected by the dose adjustment. Subjects receiving corticosteroids at baseline will start tapering their corticosteroids at Week 8 (the end of the Induction Phase) if they achieve clinical response, defined as a decrease from baseline of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1 in the MMS. The endoscopy subscore assessed by the investigator will be used for the calculation of the Week 8 MMS.

The study will consist of 4 phases:

  • Screening Phase - up to 4 weeks
  • Induction Phase - 8 weeks
  • Extension Phase - 44 weeks
  • Observational Follow-up Phase - 4 weeks Subjects who complete the Extension Phase, and those subjects who prematurely discontinue from the study for any reason, will enter the post-treatment Observational Follow-up Phase, the 4-week period after the last dose of Investigational Product(IP). The study will be conducted in compliance with International Conference on Harmonisation (ICH) Good Clinical Practices (GCPs).
Being tested
GED-0301
Keywords
Ulcerative Colitis, GED-0301, Mongersen, Efficacy, Safety
Medical subject headings
Colitis, Ulcerative

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GED-0301Drug

    Also called Mongersen

Study groups in NCT02601300
Study groupRoleWhat they receive
GED-0301 160 mg once daily (QD)ExperimentalPatients will receive oral GED-0301 160 mg once daily (QD)for duration of 52 week treatment.
Receives: Drug: GED-0301

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Score (MMS) at Week 8

    Clinical remission was defined as a modified Mayo score of ≤ 2, with no individual subscore > 1, at Week 8. The MMS was based on a modification of the total Mayo score (TMS) which included the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the Physician's Global Assessment (PGA) subscore, since this was a global measure that is subjective in nature. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The endoscopy subscores was centrally reviewed. Two-sided confidence intervals for the within-group percentage were based on the Wilson score method.

    Measured: Baseline to Week 8

Secondary outcomes (8)

  1. Percentage of Participants Who Achieved a Modified Mayo Score of ≤ 2, With Rectal Bleeding Subscore (RBS) of 0 and Stool Frequency Subscore (SFS) and Mayo Endoscopic Subscore ≤ 1 at Week 8

    A MMS was used to evaluate disease activity using 3 components: stool frequency, rectal bleeding and endoscopy; the MMS ranges from 0-9 with higher scores indicating greater disease severity.

    Stool frequency subscore was defined as 0-3:

    0 = Normal number of stools for patient

    1. = 1-2 stools per day more than normal
    2. = 3-4 stools more than normal
    3. = 5 or more stools more than normal

    Rectal bleeding (subscore 0-3) was defined as:

    0 = No blood seen

    1. = Streaks of blood with stool less than half the time
    2. = Obvious blood with stool most of the time
    3. = Blood alone passes

    Endoscopic subscore: Findings were defined as:

    0 = Normal or inactive disease

    1. = Mild Disease (erythema, decreased vascular pattern, mild friability)
    2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions)
    3. = Severe Disease (spontaneous bleeding, ulceration)

    Measured: Baseline to Week 8

  2. Percentage of Participants Who Achieved a Mayo Endoscopic Subscore of ≤ 1 at Week 8

    A Mayo endoscopic subscore of ≤ 1 was assessed and evaluated in participants who achieved a Mayo endoscopic subscore at Week 8. The endoscopy subscore findings are defined as:

    0 = Normal or inactive disease

    1. = Mild Disease (erythema, decreased vascular pattern, mild friability)
    2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions)
    3. = Severe Disease (spontaneous bleeding, ulceration) The endoscopy scores were centrally reviewed. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.

    Measured: Baseline to Week 8

  3. Percentage of Participants Who Achieved a Mayo Endoscopic Subscore of ≤ 1 by Individual Segment at Week 8

    A Mayo endoscopic subscore by individual segment (rectum, sigmoid, descending colon, transverse colon, ascending colon/cecum) of ≤ 1 was evaluated at week 8.

    The endoscopy subscore findings are defined as:

    0 = Normal or inactive disease

    1. = Mild Disease (erythema, decreased vascular pattern, mild friability)
    2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions)
    3. = Severe Disease (spontaneous bleeding, ulceration) The endoscopy scores were centrally reviewed. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.

    Measured: Baseline to Week 8

  4. Percentage of Participants Who Achieved a Clinical Response in the Modified Mayo Score at Week 8

    Clinical response in the MMS was defined as a decrease from baseline in the MMS of at least 2 points and at least 25%, along with a reduction in the RBS of at least 1 point or an absolute RBS ≤ 1. The MMS was based on the stool frequency, rectal bleeding, and endoscopic subscores of the TMS and excluded the PGA subscore. The MMS ranges from 0 to 9 points with higher scores indicating greater disease severity. The RBS was defined as:

    0 = No blood seen

    1. = Streaks of blood with stool less than half the time
    2. = Obvious blood with stool most of the time
    3. = Blood alone passes The daily bleeding score represents the most severe bleeding score represents the most severe bleeding of the day.

    Measured: Baseline to Week 8

  5. Percentage of Participants Who Achieved a Mayo Endoscopic Response at Week 8

    Endoscopic response was defined as a decrease from baseline of at least 1 point in the Mayo endoscopic subscore. The Mayo endoscopy subscore findings are defined as:

    0 = Normal or inactive disease

    1. = Mild Disease (erythema, decreased vascular pattern, mild friability)
    2. = Moderate Disease (marked erythema, lack of vascular pattern, friability erosions)
    3. = Severe Disease (spontaneous bleeding, ulceration) The endoscopy subscores were centrally reviewed. Two-sided 95% CIs for the within-group percentage were based on the Wilson score method.

    Measured: Baseline and Week 8

  6. Percentage of Participants Who Achieved a Clinical Remission in the Total Mayo Score (TMS) at Week 8

    Clinical remission in total Mayo score was defined as a total Mayo score of ≤ 2, with no individual subscore >1. The TMS is an instrument designed to measure disease activity of ulcerative colitis. The TMS ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.

    • Stool frequency subscore (SFS)
    • Rectal bleeding subscore (RBS)
    • Endoscopic subscore
    • Physician's Global Assessment (PGA)

    Measured: Baseline to Week 8

  7. Percentage of Participants Who Achieved a Clinical Response in the Total Mayo Score at Week 8

    Clinical response in the TMS was defined as a decrease from baseline in the TMS of ≥ 3 points and ≥ 30%, along with a reduction in the RBS of ≥ 1 point or an absolute RBS of ≤ 1 at Week 8. The TMS is an instrument designed to measure disease activity of ulcerative colitis. The TMS ranges from 0 to 12 points. It consists of 4 subscores, each graded from 0 to 3 with higher scores indicating more severe disease.

    • Stool frequency subscore
    • Rectal bleeding subscore
    • Endoscopic subscore
    • Physician's Global Assessment

    Measured: Baseline to Week 8

  8. The Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAE)

    A TEAE was defined as any adverse event (AE) occurring or worsening on or after the first treatment of mongersen and up to 28 days after the last mongersen dose or the last follow-up date, whichever occurred earlier. A serious AE = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was assessed by the investigator and based on the following scale: Mild = asymptomatic or mild symptoms; clinical or diagnostic observations only; Moderate = Symptoms cause moderate discomfort; Severe (could be non-serious or serious) = symptoms causing severe discomfort/pain.

    Measured: From the first day of mongersen until 28 days after the last dose of IP or at follow-up visit, whichever occurred earlier; maximum duration of treatment was 56 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Nov 2015 (estimated)
  2. Study start14 Dec 2015
  3. Primary completion6 Sep 2016
  4. Study completion8 Aug 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
41 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02601300
Sponsor's protocol ID
GED-0301-UC-002
Status last verified
Oct 2018
First submitted
6 Nov 2015
Last updated
17 Oct 2018
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing GED-0301 in people with Colitis, Ulcerative, run by Celgene at 36 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 19 inclusion and 27 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 36 sites in United States, Slovakia, Poland, Bulgaria, Canada and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 12 Sep 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Who Achieved Clinical Remission in the Modified Mayo Score (MMS) at Week 8 (time frame: Baseline to Week 8). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02601300.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Oct 2018.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in